Ticker >

NGL Fine-Chem share price

NGL Fine-Chem Ltd.

NSE: NGLFINE BSE: 524774 SECTOR: Pharmaceuticals & Drugs  35k   249   36

1960.60
-35.25 (-1.77%)
NSE: 29 Sep 03:45 PM

Price Summary

Today's High

₹ 2008

Today's Low

₹ 1950

52 Week High

₹ 2439.95

52 Week Low

₹ 1175.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

1211.26 Cr.

Enterprise Value

1230.81 Cr.

No. of Shares

0.62 Cr.

P/E

44.22

P/B

5.19

Face Value

₹ 5

Div. Yield

0.09 %

Book Value (TTM)

₹  377.67

CASH

12.95 Cr.

DEBT

32.5 Cr.

Promoter Holding

73.53 %

EPS (TTM)

₹  44.34

Sales Growth

-13.69%

ROE

9.31 %

ROCE

11.5%

Profit Growth

-61.49 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-13.69%
3 Year21.81%
5 Year19.33%

Profit Growth

1 Year-61.61%
3 Year24.49%
5 Year9.67%

ROE%

1 Year9.31%
3 Year27.13%
5 Year23.38%

ROCE %

1 Year11.5%
3 Year32.7%
5 Year27.88%

Debt/Equity

0.1441

Price to Cash Flow

37.99

Interest Cover Ratio

15.5544977019041

CFO/PAT (5 Yr. Avg.)

0.647994129278072

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2023 73.53 0
Mar 2023 73.53 0
Dec 2022 73.81 0
Sep 2022 73.81 0
Jun 2022 73.81 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 23.7983665506064% for the Past 3 years.
  • The company has shown a good revenue growth of 21.8103748093056% for the Past 3 years.
  • Company has been maintaining healthy ROE of 27.1336564614143% over the past 3 years.
  • Company has been maintaining healthy ROCE of 32.7020613287783% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 15.5544977019041.
  • The company has an efficient Cash Conversion Cycle of 74.0335132365481 days.
  • Company has a healthy liquidity position with current ratio of 2.81004455459527.
  • The company has a high promoter holding of 73.53%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.05159351440522.

 Limitations

 Looks like the company does not have any serious limitations.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023
Net Sales 63.58 64.95 69.8 72.94 69.11
Total Expenditure 63.46 60.2 62.37 62.31 61.51
Operating Profit 0.11 4.75 7.43 10.64 7.6
Other Income 3.01 4.1 2.95 2.69 3.8
Interest 0.5 0.12 0.26 0.32 0.24
Depreciation 1.96 2.02 2 1.92 2
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.67 6.71 8.12 11.08 9.16
Tax 0.16 1.75 2.03 2.55 1.36
Profit After Tax 0.51 4.96 6.09 8.53 7.81
Adjusted EPS (Rs) 0.83 8.04 9.86 13.81 12.64

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 153.17 152.18 258.18 318.67 275.05
Total Expenditure 120.88 131.27 181.13 252.75 246.34
Operating Profit 32.3 20.91 77.05 65.92 28.71
Other Income 4.12 3.34 8.55 12.64 7.61
Interest 2.55 2.62 2.2 1.91 1.83
Depreciation 6.3 7.27 7.39 7.67 7.9
Exceptional Items 0 0 0 0 0
Profit Before Tax 27.57 14.35 76 68.97 26.6
Tax 7.44 3.75 20.53 16.73 6.48
Net Profit 20.13 10.39 55.33 52.19 20.04
Adjusted EPS (Rs.) 32.58 17.16 89.79 84.57 32.57

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 3.09 3.09 3.09 3.09 3.09
Total Reserves 89.03 98.12 152.36 203.48 222.43
Borrowings 8.01 8.32 6.13 3.44 2.07
Other N/C liabilities 3.89 3.26 5 4.6 3.87
Current liabilities 45.18 42.79 39.21 63.12 56.65
Total Liabilities 149.21 155.58 205.8 277.72 288.11
Assets
Net Block 60.94 60.85 57.53 58.68 59.49
Capital WIP 0 0 0.91 6.31 26.31
Intangible WIP 0 0 0 0 0
Investments 0 3.73 3.73 3.73 3.73
Loans & Advances 1.81 8.35 20.17 36.4 35.01
Other N/C Assets 0.04 0.01 0 2.57 4.39
Current Assets 86.41 82.65 123.47 170.04 159.19
Total Assets 149.21 155.58 205.8 277.72 288.11
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 27.57 14.35 76 68.97 26.6
Adjustment 7.87 11 3.25 6.63 5.91
Changes in Assets & Liabilities -19.15 -1.98 -32.15 -43.06 5.86
Tax Paid -7.44 -3.75 -20.53 -16.73 -6.48
Operating Cash Flow 8.85 19.62 26.57 15.82 31.89
Investing Cash Flow -9.54 -18.78 -23.79 -16.13 -23.62
Financing Cash Flow 0 -1.3 -1.08 -1.08 -1.08
Net Cash Flow -0.7 -0.46 1.71 -1.4 7.19

Corporate Actions

Investors Details

PARTICULARS Jun 2022% Sep 2022% Dec 2022% Mar 2023% Jun 2023%
promoters 73.81 73.81 73.81 73.53 73.53
ajita nachane 11.55 11.55 11.55 11.55 11.55
pci ferrmone chemicals (i... - - - - 8.38
rahul nachane 17.54 17.54 17.54 17.54 17.54
rajesh lawande 21.89 21.89 21.89 21.89 21.89
sunita potdar 14.45 14.45 14.45 14.18 14.18
pci ferrmone chemicals (i... 8.38 - 8.38 8.38 -
pci fermrmone chemcials (... - 8.38 - - -
pci ferrmone chemicals (i... 8.38 - 8.38 8.38 -
PARTICULARS Mar 2022% Jun 2022% Dec 2022% Mar 2023% Jun 2023%
investors 26.19 26.19 26.19 26.47 26.47
debashish neogi - - - 1.01 1.10
llp 0.01 0.02 0.01 0.03 0.03

Annual Reports

Ratings & Research Reports

Company Presentations

  • ConcallQ1FY21 28 Sep 2020
  • PresentationQ4FY22 6 May 2022
  • PresentationQ4FY21 10 Jun 2021
  • PresentationQ4FY21 10 Jun 2021
  • PresentationQ3FY23 1 Mar 2023
  • PresentationQ3FY22 11 Feb 2022
  • PresentationQ2FY23 6 Jan 2023
  • PresentationQ2FY22 22 Nov 2021
  • PresentationQ1FY22 6 Aug 2021

Company News

NGL Fine-Chem informs about closure of trading window28 Sep 2023, 2:35PM NGL Fine-Chem informs about disclosure 18 Sep 2023, 10:27AM NGL Fine-Chem informs about disclosure 13 Sep 2023, 2:02PM NGL Fine-Chem informs about disclosure11 Sep 2023, 1:16PM NGL Fine-Chem informs about disclosure 8 Sep 2023, 5:20PM NGL Fine-Chem - Quaterly Results4 Aug 2023, 7:17PM NGL Fine-Chem - Quaterly Results4 Aug 2023, 7:17PM NGL Fine-Chem informs about details of loss of certificate28 Jul 2023, 4:29PM NGL Fine-Chem informs about credit rating 18 Jul 2023, 2:19PM NGL Fine-Chem informs about closure of trading window28 Jun 2023, 4:40PM NGL Fine-Chem informs about details of loss of certificate6 Jun 2023, 12:31PM NGL Fine-Chem - Quaterly Results15 May 2023, 6:24PM NGL Fine-Chem - Quaterly Results15 May 2023, 6:24PM NGL Fine-Chem informs about conference call12 May 2023, 3:31PM NGL Fine-Chem informs about certificate19 Apr 2023, 4:23PM NGL Fine-Chem informs about disclosure22 Mar 2023, 12:33PM Ngl Fine-Chem informs about loss of share certificate16 Mar 2023, 4:57PM Ngl Fine-Chem informs about disclosure25 Feb 2023, 3:41PM NGL Fine-Chem informs about disclosure25 Feb 2023, 11:32AM NGL Fine-Chem informs about disclosure 22 Feb 2023, 12:16PM NGL Fine-Chem - Quaterly Results10 Feb 2023, 6:14PM NGL Fine-Chem - Quaterly Results10 Feb 2023, 6:14PM NGL Fine-Chem informs about board meeting 30 Jan 2023, 12:22PM Ngl Fine-Chem informs about trading window closure28 Dec 2022, 3:30PM NGL Fine-Chem - Quaterly Results28 Oct 2022, 6:48PM NGL Fine-Chem - Quaterly Results28 Oct 2022, 6:48PM Ngl Fine-Chem informs about loss of share certificate13 Oct 2022, 4:56PM NGL Fine-Chem informs about analyst meet29 Sep 2022, 12:17PM Ngl Fine-Chem informs about loss of share certificate22 Sep 2022, 4:54PM NGL Fine-Chem informs about transcript of conference call20 Aug 2022, 10:31AM NGL Fine-Chem - Quaterly Results10 Aug 2022, 7:27PM NGL Fine-Chem - Quaterly Results10 Aug 2022, 7:27PM NGL Fine-Chem informs about certificate2 Jul 2022, 11:44AM NGL Fine-Chem informs about closure of trading window28 Jun 2022, 3:25PM NGL Fine-Chem informs about details of loss of certificate6 Jun 2022, 3:57PM NGL Fine-Chem informs about details of loss of certificate 30 May 2022, 1:49PM NGL Fine-Chem informs about non-applicability of large corporate entity13 May 2022, 2:42PM NGL Fine-Chem informs about investors conference call4 May 2022, 4:53PM NGL Fine-Chem - Quaterly Results2 May 2022, 6:47PM NGL Fine-Chem - Quaterly Results2 May 2022, 6:47PM NGL Fine-Chem informs about certificate16 Apr 2022, 11:29AM NGL Fine-Chem informs about loss of share certificate15 Mar 2022, 4:56PM NGL Fine-Chem informs about outcome of conference call9 Feb 2022, 4:51PM NGL Fine-Chem - Quaterly Results7 Feb 2022, 6:06PM NGL Fine-Chem - Quaterly Results7 Feb 2022, 6:06PM NGL Fine-Chem informs about newspaper publication1 Jan 2022, 3:19PM NGL Fine-Chem informs about closure of trading window30 Dec 2021, 1:36PM Ngl Fine-Chem informs about credit rating24 Dec 2021, 1:44PM Ngl Fine-Chem informs about loss of share certificates21 Dec 2021, 12:17PM Ngl Fine-Chem informs about disclosure15 Dec 2021, 3:33PM

NGL Fine-Chem Stock Price Analysis and Quick Research Report. Is NGL Fine-Chem an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into NGL Fine-Chem and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 31.8862 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. NGL Fine-Chem has a Debt to Equity ratio of 0.1441 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In NGL Fine-Chem , the EPS growth was -61.4926816809076 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, NGL Fine-Chem has OPM of 10.4394252006435 % which is a bad sign for profitability.
     
  • ROE: NGL Fine-Chem have a poor ROE of 9.31238066584121 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Last Updated on:
Brief about NGL Fine-Chem
X